<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="11" ids="26333">Prostaglandin</z:chebi> (PG) E2 plays a critical role in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) progression, including epithelial-mesenchymal transition (EMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Activity of the rate-limiting enzyme for <z:chebi fb="0" ids="15551">PGE2</z:chebi> catabolism (15-hydroxyprostaglandin dehydrogenase [15-PGDH]) is dependent on availability of <z:chebi fb="0" ids="13389">NAD</z:chebi>+ </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the hypothesis that there is intra-tumoral variability in <z:chebi fb="0" ids="15551">PGE2</z:chebi> content, as well as in levels and activity of 15-PGDH, in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (CRCLM) </plain></SENT>
<SENT sid="3" pm="."><plain>To understand possible underlying mechanisms, we investigated the relationship between <z:mp ids='MP_0005039'>hypoxia</z:mp>, 15-PGDH and <z:chebi fb="0" ids="15551">PGE2</z:chebi> in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Tissue from the periphery and centre of 20 human CRCLM was analysed for <z:chebi fb="0" ids="15551">PGE2</z:chebi> levels, 15-PGDH and cyclooxygenase (COX)-2 expression, 15-PGDH activity, and <z:chebi fb="0" ids="13389">NAD</z:chebi>+/<z:chebi fb="0" ids="16908">NADH</z:chebi> levels </plain></SENT>
<SENT sid="5" pm="."><plain>EMT of LIM1863 human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells was induced by transforming growth factor (TGF) β </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="15551">PGE2</z:chebi> levels were significantly higher in the centre of CRCLM compared with peripheral tissue (P = 0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>There were increased levels of 15-PGDH protein in the centre of CRCLM associated with reduced 15-PGDH activity and low <z:chebi fb="0" ids="13389">NAD</z:chebi>+/<z:chebi fb="0" ids="16908">NADH</z:chebi> levels </plain></SENT>
<SENT sid="8" pm="."><plain>There was no significant <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in COX-2 protein expression </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="13389">NAD</z:chebi>+ availability controlled 15-PGDH activity in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells in vitro </plain></SENT>
<SENT sid="10" pm="."><plain><z:mp ids='MP_0005039'>Hypoxia</z:mp> induced 15-PGDH expression in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and promoted EMT, in a similar manner to <z:chebi fb="0" ids="15551">PGE2</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>Combined 15-PGDH expression and loss of membranous E-cadherin (EMT biomarker) were present in the centre of human CRCLM in vivo </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: There is significant intra-tumoral <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in <z:chebi fb="0" ids="15551">PGE2</z:chebi> content, 15-PGDH activity and <z:chebi fb="0" ids="13389">NAD</z:chebi>+ availability in human CRCLM </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumour</z:e> micro-environment (including <z:mp ids='MP_0005039'>hypoxia</z:mp>)-driven differences in <z:chebi fb="0" ids="15551">PGE2</z:chebi> metabolism should be targeted for novel treatment of advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>